We’re thrilled to announce that MOLCURE has entered into a multi-year strategic research agreement with Boehringer Ingelheim! Together, we’ll discover innovative antibody therapeutics across multiple targets using our AI-driven platform.
https://t.co/uC6jiar4ka
Meet MOLCURE at #BIO2026 in San Diego, June 22-25! Our CEO/CSO, Satoshi Tamaki, is ready to explore partnerships. Connect with us via the official partnering system!
Link in thread.
On June 16 (Tue) from 3:00 p.m. JST, our Chief Innovation Officer, Ogawa, will speak at an @illuminakk webinar (in Japanese)! He will share case studies where MOLCURE’s proprietary AI technologies and Illumina’s NGS platforms are combined to discover high-performance antibodies.
Hitachi and MOLCURE are pleased to jointly announce the full-scale launch of their co-creation toward providing services based on Hitachi’s Confidential AI Platform – designed to accelerate AI-driven drug discovery through open innovation!